Form 8-K - Current report:
SEC Accession No. 0001641172-25-011391
Filing Date
2025-05-19
Accepted
2025-05-19 08:22:57
Documents
13
Period of Report
2025-05-19
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 41397
2 EX-99.1 ex99-1.htm EX-99.1 56228
  Complete submission text file 0001641172-25-011391.txt   273476

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE awh-20250519.xsd EX-101.SCH 3011
4 XBRL LABEL FILE awh-20250519_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE awh-20250519_pre.xml EX-101.PRE 22357
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3825
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34810 | Film No.: 25961569
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)